Advertisement

Infection Control Strategies in Transplant Populations

  • S. Cutro
  • M. Phillips
  • H. W. Horowitz
Chapter

Abstract

Infection control and prevention strategies are of great importance to the healthcare system as a whole, but are even more critical in the immunocompromised host. While transplant recipients present unique challenges to clinicians and infection control practitioners alike, standard approaches to infection control are still of foremost importance in this population. The type of transplantation, degree of immune suppression, and duration of time following transplantation help determine the risk of developing infections with various pathogens, and this chapter will address potentially preventable infections as a function of time after transplantation.

During the pre-transplant period, various serologies should be obtained and a thorough medical and surgical history must be taken to identify active infections before the transplant occurs and to understand the potential organisms that may reactivate following transplantation. In the early post-transplant period, recipients are at risk for both traditional community pathogens and nosocomial pathogens, as this period may be the patient’s first significant contact with the healthcare system. Hospitals should have well-defined strategies in place to minimize transplant recipients’ exposure to potential pathogens. During the intermediate- and late-post-transplant periods, a transition from the hospital environment to the home environment occurs, with subsequent shift in exposures for the recipient. Safe living strategies at home and at work are critical to avoid infection, but these strategies must balance safety with the desire to return to a sense of normalcy post-transplant. Strategies to minimize the risk of infection during each time period relative to the transplantation are detailed in this chapter.

Keywords

Infection control and prevention Opportunistic infections 

References

  1. 1.
    Fishman JA. Infections in immunocompromised hosts and organ transplant recipients: essentials. Liver Transplant. 2011;17(Suppl 3):S34–7.CrossRefGoogle Scholar
  2. 2.
    Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie T, van de Wetering M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.PubMedGoogle Scholar
  3. 3.
    Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–51.CrossRefGoogle Scholar
  4. 4.
    Goodrich J, Bowden R, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118:173–8.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Sepkowitz K. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. Bone Marrow Transplant. 2002;29:367–71.PubMedCrossRefGoogle Scholar
  6. 6.
    Busca ASE, Giacchino M, et al. Analysis of early infectious complications in pediatric patients undergoing bone marrow transplantation. Support Care Cancer. 1999;7:253–9.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Patel R, Paya C. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10(1):86.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56(1):23–46.PubMedCrossRefGoogle Scholar
  10. 10.
    Obayashi PA. Food safety for the solid organ transplant patient: preventing foodborne illness while on chronic immunosuppressive drugs. Nutr Clin Pract. 2012;27(6):758–66.PubMedCrossRefGoogle Scholar
  11. 11.
    Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings; 2007.Google Scholar
  12. 12.
    Magauran C, Salgado C. Challenges and advances in infection control of hematopoietic stem cell transplant recipients. Infect Disord Drug Targets. 2011;11:18–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings; 2006. https://www.cdc.gov/mrsa/pdf/mdroGuideline2006.pdf
  14. 14.
    Guideline for Hand Hygiene in Health-Care Settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force MMWR: Centers for Disease Control and Prevention; 2002. p. RR-16.Google Scholar
  15. 15.
    Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Kusnea S, Krystofiak S. Infection control issues after bone marrow transplantation. Curr Opin Infect Dis. 2001;14:427–31.CrossRefGoogle Scholar
  17. 17.
    Morris M. Pre-transplant recipient evaluation & management. http://www.antimicrobe.org/final/t33.asp. Cited 14 Aug 2016.
  18. 18.
    Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin N Am. 2010;24(2):273–83.CrossRefGoogle Scholar
  19. 19.
    Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis. 2002;35:1513–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Shaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clin Infect Dis. 2001;33(Suppl 1):S9–14.CrossRefGoogle Scholar
  21. 21.
    Services USDoHaH. Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps). In: Administration FaD, editor; 2007.Google Scholar
  22. 22.
    Casas S, Muñoz L, Moure R, Castellote J, Guerra MR, Gonzalez L, et al. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB gold in-tube test for the screening of tuberculosis infection before liver transplantation. Liver Transplant. 2011;17(10):1205–11.CrossRefGoogle Scholar
  23. 23.
    Theodoropoulos N, Lanternier F, Rassiwala J, McNatt G, Preczewski L, DeMayo E, et al. Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: a single-center retrospective study. Transplant Infect Dis. 2012;14(1):1–8.CrossRefGoogle Scholar
  24. 24.
    Russo RL, Dulley FL, Suganuma L, Franca IL, Yasuda MA, Costa SF. Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature. Int J Infect Dis. 2010;14(Suppl 3):e187–91.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Ferrara G, Losi M, D’Amico R, Roversi P, Piro R, Meacci M, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006;367(9519):1328–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Kim SY, Jung GS, Kim SK, Chang J, Kim MS, Kim YS, et al. Comparison of the tuberculin skin test and interferon-gamma release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection. 2013;41(1):103–10.CrossRefGoogle Scholar
  27. 27.
    Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR: Centers for Disease Control and Prevention; 2000.Google Scholar
  28. 28.
    Partridge-Hinckley K, Liddell GM, Almyroudis NG, Segal BH. Infection control measures to prevent invasive mould diseases in hematopoietic stem cell transplant recipients. Mycopathologia. 2009;168(6):329–37.PubMedCrossRefGoogle Scholar
  29. 29.
    Immunization of Health-Care Personnel Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR: Centers for Disease Control and Prevention; 2011. p. 1–46.Google Scholar
  30. 30.
    Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521–6.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Bolyard E, Tablan O, Williams W, Pearson ML, Shapiro C, Deitchman S, et al. Guideline for infection control in healthcare personnel. Infect Control Hosp Epidemiol. 1998;19:407–63.PubMedCrossRefGoogle Scholar
  32. 32.
    Bischoff WE, Swett K, Leng I, Peters TR. Exposure to influenza virus aerosols during routine patient care. J Infect Dis. 2013;207(7):1037–46.PubMedCrossRefGoogle Scholar
  33. 33.
    Noti JD, Lindsley WG, Blachere FM, Cao G, Kashon ML, Thewlis RE, et al. Detection of infectious influenza virus in cough aerosols generated in a simulated patient examination room. Clin Infect Dis. 2012;54(11):1569–77.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Yokoe D, Casper C, Dubberke E, Lee G, Munoz P, Palmore T, et al. Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant. 2009;44(8):495–507.PubMedCrossRefGoogle Scholar
  35. 35.
    Huang S, Yokoe D, Hinrichsen V, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2006;43:971–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Russell DL, Flood A, Zaroda TE, Acosta C, Riley MM, Busuttil RW, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant. 2008;8(8):1737–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Singh N, Squier C, Wannstedt C, et al. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol. 2006;27:122–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Patel G, Perez F, Bonomo RA. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation. Curr Opin Organ Transplant. 2010;15(6):676–82.PubMedCrossRefGoogle Scholar
  39. 39.
    Bert F, Larroque B, Paugam-Burtz C, Dondero F, Durand F, Marcon E, et al. Pretransplant fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis. 2012;18(6):908–16.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Banach D, Bearman G, Barnden M, Hanrahan J, Leekha S, Morgan D, Wiemken T. Duration of contact precautions for acute-care settings. Infect Control Hosp Epidemiol. 2018;39(2):127–44. https://doi.org/10.1017/ice.2017.245 CrossRefGoogle Scholar
  41. 41.
    Hicheri Y, Einsele H, Martino R, Cesaro S, Ljungman P, Cordonnier C. Environmental prevention of infection in stem cell transplant recipients: a survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Transpl Infect Dis. 2013;15(3):251–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Mattner F, Biertz F, Ziesing S, Gastmeier P, Chaberny IF. Long-term persistence of MRSA in re-admitted patients. Infection. 2010;38(5):363–71.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Sohn KM, Peck KR, Joo EJ, Ha YE, Kang CI, Chung DR, et al. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. Int J Infect Dis. 2013;17(4):e240–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Schechner V, Kotlovsky T, Tarabeia J, Kazma M, Schwartz D, Navon-Venezia S, et al. Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter. Infect Control Hosp Epidemiol. 2011;32(5):497–503.PubMedCrossRefGoogle Scholar
  45. 45.
    Zimmerman FS, Assous MV, Bdolah-Abram T, Lachish T, Yinnon AM, Wiener-Well Y. Duration of carriage of carbapenem-resistant Enterobacteriaceae following hospital discharge. Am J Infect Control. 2013;41(3):190–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Hayes-Lattin B, Leis JF, Maziarz RT. Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transplant. 2005;36(5):373–81.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Cornet M, Levy V, Fleury L, Lortholary J. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol. 1999;20(7):508–13.PubMedCrossRefGoogle Scholar
  48. 48.
    Sehulster LM, Chinn RYW, Arduino MJ, Carpenter J, Donlan R, Ashford D, Besser R, Fields B, McNeil MM, Whitney C, Wong S, Juranek D, Cleveland J. Guidelines for environmental infection control in health-care facilities. Recommendations from CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC); 2004. www.cdc.gov/ncidod/hip/enviro/guidehtm
  49. 49.
    Walsh T, Dixon D. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis, and treatment. Eur J Epidemiol. 1989;5:131–42.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Russell J, Chaudhry A, Booth K. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant. 2000;6(2):109–14.PubMedCrossRefGoogle Scholar
  51. 51.
    Fernandez-Aviles F, Carreras E, Urbano-Ispizua A, Rovira M, Martinez C, Gaya A, et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol. 2006;24(30):4855–61.PubMedCrossRefGoogle Scholar
  52. 52.
    Russell J, Poon M-C, Jones A, Woodman R, Ruether B. Allogeneic bone-marrow transplantation without protective isolation in adults with malignant disease. Lancet. 1992;339:38–40.PubMedCrossRefGoogle Scholar
  53. 53.
    Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P, et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002;100(13):4317–24.PubMedCrossRefGoogle Scholar
  54. 54.
    Mayhall CG. Hospital epidemiology and infection control. Philadelphia: Lippincott Williams & Wilkins; 2012.Google Scholar
  55. 55.
    Novosad SA, Vasquez A, Nambiar A, et al. Notes from the field. probable mucormycosis among adult solid organ transplant recipients at an acute care hospital—Pennsylvania, 2014–2015. MMWR Morb Mortal Wkly Rep. 2016;65:481–2.PubMedCrossRefGoogle Scholar
  56. 56.
    O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2011;39(4. Suppl 1):S1–34.PubMedCrossRefGoogle Scholar
  57. 57.
    National Healthcare Safety Network (NHSN) report, data summary for 2010, device-associated module. Centers for Disease Control and Prevention; 2010.Google Scholar
  58. 58.
    Hanna H, Benjamin R, Chatzinikolaou I, Alakech B, Richardson D, Mansfield P, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol. 2004;22(15):3163–71.PubMedCrossRefGoogle Scholar
  59. 59.
    Maaskant JM, De Boer JP, Dalesio O, Holtkamp MJ, Lucas C. The effectiveness of chlorhexidine-silver sulfadiazine impregnated central venous catheters in patients receiving high-dose chemotherapy followed by peripheral stem cell transplantation. Eur J Cancer Care. 2009;18(5):477–82.CrossRefGoogle Scholar
  60. 60.
    George S, Vuddamalay P, Boscoe M. Antiseptic-impregnated central venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. Eur J Anaesthesiol. 1997;14:428–31.PubMedCrossRefGoogle Scholar
  61. 61.
    Timsit JF, Mimoz O, Mourvillier B, Souweine B, Garrouste-Orgeas M, Alfandari S, et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. Am J Resp Crit Care Med. 2012;186(12):1272–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Chambers ST, Sanders J, Patton WN, Ganly P, Birch M, Crump JA, et al. Reduction of exit-site infections of tunnelled intravascular catheters among neutropenic patients by sustained-release chlorhexidine dressings: results from a prospective randomized controlled trial. J Hosp Infect. 2005;61(1):53–61.PubMedCrossRefGoogle Scholar
  63. 63.
    Aitken C, Jeffries DJ. Nosocomial spread of viral disease. Clin Microbiol Rev. 2001;14(3):528–46.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Weigt SS, Gregson AL, Deng JC, Lynch JP 3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med. 2011;32(4):471–93.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Raboni SM, Nogueira MB, Tsuchiya LR, Takahashi GA, Pereira LA, Pasquini R, et al. Respiratory tract viral infections in bone marrow transplant patients. Transplantation. 2003;76(1):142–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Martin ST, Torabi MJ, Gabardi S. Influenza in solid organ transplant recipients. Ann Pharmacother. 2012;46(2):255–64.PubMedCrossRefGoogle Scholar
  67. 67.
    Antiviral agents for the treatment and chemoprophylaxis of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR: Centers for Disease Control and Prevention; 2011.Google Scholar
  68. 68.
    Roos-Weil D, Ambert-Balay K, Lanternier F, Mamzer-Bruneel MF, Nochy D, Pothier P, et al. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation. 2011;92(1):61–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Henke-Gendo C, Harste G, Juergens-Saathoff B, Mattner F, Deppe H, Heim A. New real-time PCR detects prolonged norovirus excretion in highly immunosuppressed patients and children. J Clin Microbiol. 2009;47(9):2855–62.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Schorn R, Hohne M, Meerbach A, Bossart W, Wuthrich RP, Schreier E, et al. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. Clin Infect Dis. 2010;51(3):307–14.PubMedCrossRefGoogle Scholar
  71. 71.
    Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med. 2012;367(22):2126–32.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Zuckerman RA, Limaye AP. Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant. 2013;13(Suppl 3):55–66; quiz.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Donnelly JP. Infection prevention – protected environment and infection control. In: Safdar A, editor. Principles and practice of cancer infectious diseases. New York: Humana Press; 2011. p. 541–50.CrossRefGoogle Scholar
  74. 74.
    Trifilio S, Helenowski I, Giel M, Gobel B, Pi J, Greenberg D, et al. Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(9):1385–90.PubMedCrossRefGoogle Scholar
  75. 75.
    FDA food code: US Food and Drug Administration; 2013. Available from: http://www.fda.gov/downloads/Food/GuidanceRegulation/RetailFoodProtection/FoodCode/UCM374510.pdf. Cited 24 Aug 2016.
  76. 76.
    O’Connor KA, Kingston M, O’Donovan M, Cryan B, Twomey C, O’Mahony D. Antibiotic prescribing policy and Clostridium difficile diarrhoea. QJM. 2004;97(7):423–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779–95.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Basic infection control and prevention plan for outpatient oncology settings: Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/HAI/settings/outpatient/basic-infection-control-prevention-plan-2011/index.html. Cited 14 Aug 2016.
  79. 79.
    Sipsas NV, Kontoyiannis DP. Occupation, lifestyle, diet, and invasive fungal infections. Infection. 2008;36(6):515–25.PubMedCrossRefGoogle Scholar
  80. 80.
    Kotton CN, Ryan ET, Fishman JA. Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant. 2005;5(1):8–14.PubMedCrossRefGoogle Scholar
  81. 81.
    Avery RK, Michaels MG. Strategies for safe living following solid organ transplantation. Am J Transplant. 2009;9(Suppl 4):S252–7.PubMedCrossRefGoogle Scholar
  82. 82.
    Cescon DP, AV; Richardson S, Moore MJ. Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol. 2008;26(13):2214–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Szyper-Kravitz M, Lang R, Manor Y, Lahav M. Early invasive pulmonary aspergillosis in a leukemia patient linked to aspergillus contaminated marijuana smoking. Leuk Lymphoma. 2001;42:1433–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Food safety for transplant recipients: US Food and Drug Administration; 2011. Available from: http://www.fda.gov/Food/ResourcesForYou/Consumers/SelectedHealthTopics/ucm312570.htm. Cited 14 Aug 2016.
  85. 85.
    The Yellow Book: Centers for Disease Control and Prevention; 2012. Available from: http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-2-the-pre-travel-consultation/the-pre-travel-consultation.htm. Cited 14 Aug 2016.
  86. 86.
    Lortholary O, Charlier C, Lebeaux D, Lecuit M, Consigny PH. Fungal infections in immunocompromised travelers. Clin Infect Dis. 2013;56(6):861–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Kontoyiannis DP. Preventing fungal disease in chronically immunosuppressed outpatients: time for action? Ann Intern Med. 2013;158(7):555–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601–14.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am. 2011;25(1):101–16.PubMedCrossRefGoogle Scholar
  90. 90.
    Guides for people at risk of foodborne illness: food and drug administration; 2012. Available from: http://www.fda.gov/Food/ResourcesForYou/Consumers/SelectedHealthTopics/default.htm
  91. 91.
    Lund BM, O’Brien SJ. Microbiological safety of food in hospitals and other healthcare settings. J Hospital Infect. 2009;73(2):109–20.CrossRefGoogle Scholar
  92. 92.
    Cutro SR, Dean R, Phillips MS. Implementation of a restricted foods policy at a large academic medical center. Infect Control Hosp Epidemiol. 2014;35(6):749–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • S. Cutro
    • 1
  • M. Phillips
    • 2
  • H. W. Horowitz
    • 3
  1. 1.Department of Infectious DiseasesThe Southeast Permanente Medical Group, Kaiser PermanenteAtlantaUSA
  2. 2.New York University School of Medicine, Division of Infectious Diseases and ImmunologyNew YorkUSA
  3. 3.Department of Medicine, Division of Infectious Diseases,New York Presbyterian-Brooklyn Methodist Hospital, Weill Cornell Medical CollegeBrooklynUSA

Personalised recommendations